Optimer/Cubist’s Dificid poised to challenge Vancocin usage in C. difficile treatment; report


Less than half of surveyed infectious disease (ID) specialists and only 6% of surveyed internists demonstrated…

Antibiotics and Infectious diseasesCubist PharmaceuticalsDificidMarkets & MarketingNorth AmericaOptimer PharmaceuticalsPharmaceuticalVancocin

US FDA approves Optimer’s Dificid for C. difficile infection


Following a positive advisory panel recommendation last month, the US Food and Drug Administration has…

Antibiotics and Infectious diseasesCubist PharmaceuticalsDificidNorth AmericaOptimer PharmaceuticalsPharmaceuticalRegulation

US FDA advisory panel backs Optimer novel antibiotic Dificid for CDI


The US Food and Drug Administration's Anti-Infective Drugs Advisory Committee has recommended that the…

Antibiotics and Infectious diseasesCubist PharmaceuticalsDificidfidaxomicinNorth AmericaOptimer PharmaceuticalsPharmaceuticalRegulation

Back to top